indoramin
{{short description|Chemical compound}}
{{Drugbox
| IUPAC_name = N-
| image = Indoramin.svg
| tradename =
| Drugs.com = {{drugs.com|international|indoramin}}
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 26844-12-2
| ATC_prefix = C02
| ATC_suffix = CA02
| PubChem = 33625
| IUPHAR_ligand = 501
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08950
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 31014
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0Z802HMY7H
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04531
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 279516
| C=22 | H=25 | N=3 | O=1
| smiles = O=C(c1ccccc1)NC4CCN(CCc3c2ccccc2[nH]c3)CC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JXZZEXZZKAWDSP-UHFFFAOYSA-N
}}
Indoramin (trade names Baratol and Doralese) is a piperidine antiadrenergic agent.
It is an alpha-1 selective adrenoceptor antagonist{{cite journal | vauthors = Pierce V, Shepperson NB, Todd MH, Waterfall JF | title = Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin | journal = British Journal of Pharmacology | volume = 87 | issue = 2 | pages = 433–441 | date = February 1986 | pmid = 3955309 | pmc = 1916533 | doi = 10.1111/j.1476-5381.1986.tb10834.x }} with direct myocardial depression action; therefore, it results in no reflex tachycardia. It is also used in benign prostatic hyperplasia (BPH).{{cite web|url=http://www.medicines.org.uk/Guides/indoramin%20hydrochloride/prostatic%20hyperplasia%20(benign)|title=Indoramin 20mg tablets|publisher=Medicines.org.uk|date=April 20, 2011|access-date=September 30, 2012|archive-date=July 25, 2022|archive-url=https://web.archive.org/web/20220725151921/https://www.medicines.org.uk/Guides/indoramin%20hydrochloride/prostatic%20hyperplasia%20(benign)|url-status=dead}}
It is commonly synthesized from tryptophol.Ullman's encyclopedia of Industrial Chemistry, Sixth Edition, 2002.
Dosage
Indoramin is commonly prescribed as 20 mg tablets when used in BPH.{{cite web|url=http://www.nhs.uk/medicine-guides/pages/MedicineOverview.aspx?condition=Prostatic%20hyperplasia%20(benign)&medicine=indoramin%20hydrochloride|title=Indoramin hydrochloride|publisher=National Health Service (UK)|access-date=September 30, 2012}}
Side Effects
Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain, hypotension, postural hypotension, depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, and palpitations.{{cite web|url=https://www.medicines.org.uk/emc/product/6666|title=Indoramin 20mg tablets|publisher=Medicines.org.uk|access-date=February 7, 2018}}
Synthesis
Tryptamine and serotonin are naturally occurring indole ethylamino compounds with pronounced pharmacological activities. They have served as the inspiration for synthesis of numerous analogues.
One such study involved alkylation of 4-benzamidopyridine (2) with a bromoethyy compound (1) derived from tryptophol, to give a quaternary pyridinium salt (3); this intermediate was in turn hydrogenated with a Raney nickel catalyst to give indoramine.{{Cite patent | inventor = Archibald JL, Jackson JO |country=ZA|number=6803204}}; eidem, {{US patent|3527761}} (1969, 1970 both to Wyeth).{{cite journal | vauthors = Archibald JL, Alps BJ, Cavalla JF, Jackson JL | title = Synthesis and hypotensive activity of benzamidopiperidylethylindoles | journal = Journal of Medicinal Chemistry | volume = 14 | issue = 11 | pages = 1054–1059 | date = November 1971 | pmid = 5115203 | doi = 10.1021/jm00293a009 }}
Product withdrawal
On May 31, 2013, the French National Agency for the Safety of Medicines and Health Products (ANSM) concluded that the benefit/risk ratio of this product was unfavorable and withdrew Vidora's marketing authorization and recalled its batches from the market on June 3, 2013.{{Cite web |title=Actualités |url=https://ansm.sante.fr/actualites/a-la-une |access-date=2023-04-17 |website=ANSM |language=fr}}
References
{{reflist}}
{{Antihypertensives and diuretics}}
{{Adrenergic receptor modulators}}
{{Tryptamines}}
Category:N,N-Dialkyltryptamines
{{antihypertensive-stub}}